SCILEX HOLDING COMPANY - COMMON STOCK

Scilex Holding Company Announces Positive Type C Meeting with the FDA and Reaches Agreement on Path Forward to File an NDA for SP-102 (SEMDEXATM) in Lumbosacral Radicular Pain (Sciatica)

02 Nov 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Generates Record Monthly Revenue In October 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended October 2023, And Year-To-Date Through October 31, 2023, Based On Currently Available Information

01 Nov 2023 09:00:00 By Nasdaq GlobeNewswire

UPDATE -- Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure

27 Oct 2023 15:38:47 By Nasdaq GlobeNewswire

Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure

27 Oct 2023 14:05:41 By Nasdaq GlobeNewswire

Scilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate Potential Naked Short Selling, Short Positions, Stock Lending Program Activities and Market Manipulation of Its Stock Price

07 Oct 2023 19:27:54 By Nasdaq GlobeNewswire

Scilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted Dividend Shares of Scilex Holding Company

04 Oct 2023 12:59:39 By Nasdaq GlobeNewswire

Scilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding Company

03 Oct 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Submits a Request to the Securities and Exchange Commission to Withdraw its Registration Statement on Form S-1 (File No. 333-271401)

27 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023

25 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.

21 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to Severe Acute Lower Back Pain (LBP)

14 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder

13 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Presented Oral and Poster Presentations on ZTlido (lidocaine topical system) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV

12 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Presented Oral and Poster Presentations on Elyxyb at the 2023 Annual Brain Week Conference Held in Las Vegas, NV

12 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently Available Information

11 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Results From Independent Market Research Study Conducted with Pain Specialists and HCPs Treating Post-Herpetic Neuralgia (PHN) Pain on ZTlido®

13 Jul 2023 09:00:01 By Nasdaq GlobeNewswire

Scilex Holding Company Generates Record Monthly Revenue In June 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended June 2023, Quarter Ended June 2023, And Year-To-Date As Of June 2023, Based On Currently Available Information

05 Jul 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company to Present Data on ELYXYB™ (celecoxib oral solution) at the 65th Annual Scientific Meeting of the American Headache Society, in Austin, TX.

16 Jun 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces that Sorrento Therapeutics, Inc.’s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock

15 Jun 2023 09:03:00 By Nasdaq GlobeNewswire

Scilex Holding Company provides certain preliminary unaudited financial results for gross and net Sales for the one month ended May 2023, and year-to-date May 2023, based on currently available information

01 Jun 2023 12:28:41 By Nasdaq GlobeNewswire